Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing...
Cancer
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
Company Announcement Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide...
Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development
BASEL, Switzerland – 17th July 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer...
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE...
CORRECTION — Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
In a release issued under the same headline on July 12, 2024 by Onco360 Oncology Pharmacy, please note the change...
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients...
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...
Radiation Detection, Monitoring, and Safety Market: $4.4 Billion by 2029, CAGR 8.3% | MarketsandMarkets™
CHICAGO, July 16, 2024 /PRNewswire/ -- The global radiation detection, monitoring, and safety market, valued at USD 2.9 billion in...
Synamics Therapeutics, AI-Driven Drug Discovery Startup, Attracts Former Novozymes Executives as Lead Investors
COPENHAGEN, Denmark, July 16, 2024 /PRNewswire/ -- Synamics Therapeutics, a groundbreaking AI-driven drug discovery startup dedicated to combating drug resistance...
Globally Unique VELA Mammography Chair, Offered by Enable Me, is an Exciting New High-Tech Tool in the Fight Against Breast Cancer
See the VELA Mammography Chair in action for the first time in Booth 208 at the Florida Radiological Association and...
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17th at 4:00 PM ET HOUSTON, TX /...
The International Myeloma Foundation Mourns the Passing of IMF Board Member and Support Group Leader Jack Aiello
STUDIO CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the...
Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs...
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE)...
Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada
July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada Biodexa Pharmaceuticals...
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to...
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to CalidiSAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE)...
Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary
MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing...